Anti-IL-17 a New Treatment for Contact Dermatititis

Phase 3 Unknown 20 enrolled Tanja Todberg, MD

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy of anti-IL 17 treatment (secukinumab) in patients with known severe allergic contact dermatitis (ACD).

Timeline

Start: 2016-01
Primary completion: 2017-06
Completion: 2017-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Secukinumab	Monoclonal antibody	300 mg	Subcutaneous

Anti-IL-17 a New Treatment for Contact Dermatititis

Summary

Timeline

Drugs

Indications